In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Nordion

Finance Watch: 14 Biopharma IPOs In One Remarkable Month

Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.

Financing Business Strategies

Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape

The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.

Deals Business Strategies

Finance Watch: ORIC Raises $120m In Another Pandemic Era Biopharma IPO

Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.

Financing Business Strategies

Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s

Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.

Innovation Clinical Trials
See All

Company Information

  • Other Names / Subsidiaries
    • MDS Inc.
UsernamePublicRestriction

Register